Journal of Drug Delivery / 2013 / Article / Tab 1

Review Article

Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

Table 1

Examples of multifunctional liposomal nanocarriers.

Encapsulated agentTargeting ligandDevelopment stageReferences

DoxorubicinNoneApproved (Doxil/Caelyx)[13]
VincristineNoneApproved (Marqibo)[14]
PaclitaxelNoneApproved (Lipusu)[15]
Cytarabine and daunorubicinNonePhase I (CPX-351)[24]
Irinotecan and floxuridineNonePhase I (CPX-1)[25]
PKN3 siRNANonePhase I (Atu-027)[26]
IrinotecanNonePhase I (NL CPT-11)[27]
DoxorubicinStomach cancer-specific anti-GAH mAbPhase I (MCC-465)[28]
OxaliplatinTransferrinPhase II (MBP-426)[29]
Liposomal p53 DNA and docetaxelAnti-Transferrin receptor scFvPhase I (SGT53-01)[30]
DoxorubicinThermoresponsive liposomesPhase III (ThermoDox)[31]
DoxorubicinCancer-specific 2C5 mAbpreclinical[32]
DoxorubicinAnti-CD22 mAbpreclinical[33]
PaclitaxelAnti-HER2 mAbpreclinical[34]
VincristinemBAFFpreclinical[35]
OxaliplatinTransferrinpreclinical[36]
DaunorubicinTransferrin and mannosepreclinical[37]
VinorelbineNSCLC-specific peptidepreclinical[38]
DoxorubicinMetastasis-specific peptidepreclinical[39]
DoxorubicinMMP-2/9 detachable PEGpreclinical[40]
IrinotecanFolic acidpreclinical[41]
DoxorubicinEstronepreclinical[42]
EtoposideChondroitin sulfatepreclinical[43]